Brown Brothers Harriman & Co’s Genelux GNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.06K Hold
1,350
﹤0.01% 1611
2026
Q1
$3.27K Hold
1,350
﹤0.01% 1606
2025
Q4
$5.89K Hold
1,350
﹤0.01% 1466
2025
Q3
$5.67K Hold
1,350
﹤0.01% 1387
2025
Q2
$3.88K Sell
1,350
-13,099
-91% -$34.6K ﹤0.01% 1300
2025
Q1
$39K Hold
14,449
﹤0.01% 867
2024
Q4
$34.1K Sell
14,449
-6,626
-31% -$17.6K ﹤0.01% 941
2024
Q3
$49.9K Buy
21,075
+9,114
+76% +$20.1K ﹤0.01% 812
2024
Q2
$23.3K Sell
11,961
-2
-0% -$7 ﹤0.01% 868
2024
Q1
$76.9K Sell
11,963
-1,689
-12% -$15.3K ﹤0.01% 686
2023
Q4
$191K Sell
13,652
-3
-0% -$47 ﹤0.01% 496
2023
Q3
$334K Buy
+13,655
New +$346K ﹤0.01% 400

Other funds holding GNLX

Brown Brothers Harriman & Co's GNLX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Genelux (GNLX) position steady in Q2 2026 at 1,350 shares worth $4.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Brown Brothers Harriman & Co first reported a position in GNLX in Q3 2023 and has held it in 12 quarters since. The position peaked at $334K in Q3 2023. 72 funds tracked by Wall St. Rank hold GNLX as of Q2 2026.

  • Brown Brothers Harriman & Co held 1,350 shares of Genelux worth $4.06K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Genelux share count unchanged in Q2 2026.
  • Genelux made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1611 holding.
  • Brown Brothers Harriman & Co first reported a position in Genelux in Q3 2023 and has held it in 12 quarters since.
  • Brown Brothers Harriman & Co's Genelux position peaked at $334K in Q3 2023.
  • 72 funds tracked by Wall St. Rank held Genelux as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.